| abstract |
This application discloses Bruton Tyrosine Kinase (BTK) inhibitors of the general formula (IM) and analogs thereof, pharmaceutical compositions containing these compounds, methods of preparing them, and use of these compounds as therapeutic agents for the treatment of various disorders related to the excessive BTK activity, including cancers, immune disorders, cardiovascular diseases, viral infections, inflammation, metabolism/endocrine function disorders, and neurological disorders. |